Global Osteoarthritis Treatment Market, By Anatomy (Hand Osteoarthritis, Knee Osteoarthritis, Hip Osteoarthritis, Small Joint Osteoarthritis), Drug Type (Prescription Drugs, Over-the-Counter Drugs), Treatment Type (Medication, Surgery, Therapy), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Injections, Others), Diagnosis (Imaging Tests, Joint Fluid Analysis, Blood Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the osteoarthritis treatment market is anticipated to grow rapidly during the forecast period. According to the World Health Organization, around 10% to 15% of all persons over the age of 60 have osteoarthritis, with women having a higher prevalence than males. According to the United Nations, adults over the age of 60 will make up more than 20% of the global population by 2050. A conservative estimate of 15 percent of this 20 percent will have symptomatic osteoarthritis, with one-third of this group seriously afflicted.
Data Bridge Market Research analyses that the osteoarthritis treatment market was valued at USD 6,214.06 million in 2021 and is expected to reach USD 10,100.30 million by 2029, registering a CAGR of 6.26% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Anatomy (Hand Osteoarthritis, Knee Osteoarthritis, Hip Osteoarthritis, Small Joint Osteoarthritis), Drug Type (Prescription Drugs, Over-the-Counter Drugs), Treatment Type (Medication, Surgery, Therapy), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Injections, Others), Diagnosis (Imaging Tests, Joint Fluid Analysis, Blood Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Perrigo Company plc (Ireland), Tolmar Pharmaceuticals, Inc. (U.S.), Reckitt Benckiser Group PLC (U.K.), Sun Pharmaceutical Industries Ltd. (India), Assertio Therapeutics, Inc. (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan)
|
|
Market Opportunities
|
|
Market Definition
The most prevalent chronic disease affecting the joints is osteoarthritis, often known as degenerative arthritis. The affected body parts experience acute joint pain and stiffness as a result of this. Osteoarthritis can be treated with a variety of methods, including exercise for joint pain relief and pain medicines. OA symptoms can be relieved with over-the-counter (OTC) pain medications such as acetaminophen (Tylenol) or a nonsteroidal anti-inflammatory drug (NSAID). Duloxetine (Cymbalta) is a prescription pain reliever that can also be used to treat long-term (chronic) OA discomfort. Steroid injections can often provide significant relief from OA pain in the short to medium term.
Osteoarthritis Treatment Market Dynamics
Drivers
- Increasing prevalence of osteoarthritis
The rising prevalence of osteoarthritis is estimated to enhance the osteoarthritis treatment market's growth. Injury, obesity, and a variety of other factors contribute to osteoarthritis. The damaged bodily part has severe joint pain and stiffness. Swelling of joints, tingling in the legs and limbs, and a reduction in range of motion are all indications of osteoarthritis. As per a study published in the Lancet Journal in November 2020, osteoarthritis affected about 7% of the global population, or more than 500 million people, in 2019, with women disproportionately affected. The number of people affected by osteoarthritis globally increased by 48 percent from 1990 to 2019, and osteoarthritis was the 15th leading cause of years lived with disability (YLDs) in 2019.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of osteoarthritis treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to getting osteoarthritis treatment, further estimated to enhance theirmarket's growth rate.
- Surging cases of joint injuries
The increasing number of joint injuries is estimated to elevate the 'market's growth rate. Osteoarthritis can be worsened by injuries sustained while participating in sports or as a result of an accident. Osteoarthritis can be triggered by injuries that occurred many years ago but appear to have healed.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the osteoarthritis treatment market. Additionally, rising incidences of orthopedic disorders and sedentary lifestyle of people will expand the osteoarthritis treatment market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities of medication for symptomatic treatment of osteoarthritis. This will provide beneficial opportunities for the osteoarthritis treatment market growth. For illustration, Flexion Therapeutics, Inc. began a Phase III investigation of FX006 32 mg, which is indicated for knee osteoarthritis, in April 2018.
Moreover, rising investment in the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the osteoarthritis treatment market growth during the forecast period.
Restraints/Challenges
- Side effects linked with Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
NSAIDs, both over-the-counter and prescribed, are commonly used to treat osteoarthritis pain. According to a report published by the National Center for Biotechnology Information in 2019, NSAIDs are administered to more than half of all osteoarthritis patients in the United States. Similarly, 60 percent of osteoarthritis patients in Europe who used prescription drugs (47 percent) received NSAIDs. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been linked to an enhanced risk of cardiovascular events. Both selective and non-selective NSAIDs (coxibs) increase the risk of cardiovascular disease in patients. These factors will impede the 'market's growth rate during the forecast period of 2021-2029.
On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the osteoarthritis treatment market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This osteoarthritis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteoarthritis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
X-rays reveal osteoarthritis in about 80% of elderly persons aged 55 and more. Approximately 60% of these people suffer from symptoms. Symptomatic osteoarthritis affects an estimated 240 million adults globally, including over 30 million adults in the United States. Knee osteoarthritis occurs more frequently in postmenopausal women than in males.
Osteoarthritis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Osteoarthritis Treatment Market
Over the projected period, the osteoarthritis treatment market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing many people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The osteoarthritis treatment market was hampered by the supply chain slowness.
Recent Development
- In December 2020, Moebius Medical had announced the US Food and Drug Administration (FDA) clearance for its investigational new drug (IND) application for initiating a global multi-center Phase IIb clinical trial of MM-II, which is a novel candidate for the treatment of pain due to knee osteoarthritis (OA).
Global Osteoarthritis Treatment Market Scope
The osteoarthritis treatment market is segmented on the basis of anatomy, drug type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Anatomy
- Hand Osteoarthritis
- Knee Osteoarthritis
- Hip Osteoarthritis
- Small Joint Osteoarthritis
Drug Type
- Prescription Drugs
- Over-the-Counter Drugs
Treatment Type
- Medication
- Duloxetine
- Acetaminophen
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
- Others
- Surgery
- Joint Replacement
- Realigning Bones
- Lubrication Injections
- Cortisone Injections
- Therapy
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Occupational Therapy
- Physical Therapy
Diagnosis
- Imaging Tests
- Magnetic resonance imaging (MRI)
- X-rays
- Joint Fluid Analysis
- Blood Tests
- Others
Dosage form
- Tablets
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Osteoarthritis Treatment Market Regional Analysis/Insights
The osteoarthritis treatment market is analysed and market size insights and trends are provided by country, anatomy, drug type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the osteoarthritis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the osteoarthritis treatment market because of the launch of new treatment options in this region. Additionally, rising healthcare expenditure along with the availability of treatment options will further propel the 'market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to presence of generic manufacturers in this region. Also, development of healthcare infrastructure and rising geriatric population will further propel the 'market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Osteoarthritis Treatment Market Share Analysis
The Osteoarthritis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteoarthritis treatment market.
Some of the major players operating in the osteoarthritis treatment market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France), Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Zydus Cadila (India)
- Boehringer Ingelheim International GmbH. (Germany)
- Apotex Inc. (Canada)
- AstraZeneca (U.K.)
- Horizon Therapeutics PLC (Ireland)
- Johnson & Johnson Private Limited (U.S.)
- Bayer AG (Germany)
- Perrigo Company plc (Ireland)
- Tolmar Pharmaceuticals, Inc. (U.S.)
- Reckitt Benckiser Group PLC (U.K.)
- Sun Pharmaceutical Industries Ltd. (India)
- Assertio Therapeutics, Inc. (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
SKU-